Ociperlimab
Based on 1 Customer Validation
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer.
For research use only. We do not sell to patients.
- Purity : 98.14%
- CAS No.: 2342597-93-5
- Molecular Weight:145.12 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TIGIT
In Vitro
Ociperlimab (BGB-A1217; 0-10 μg/mL) enhances IFN-γ secretion by cytomegalovirus-specific T cells[1].
Ociperlimab (1-1000 ng/mL) activates NK and monocytes in an Fc-dependent manner[1].
Ociperlimab removes TIGIT from T cell surface through Fc-dependent endocytosis in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26 WT tumor-bearing humanized TIGIT knock-in mice and MC38 tumor-bearing humanized TIGIT knock-in mice[1]
-
Dosage:3 and 10 mg/kg
-
Administration:Intraperitoneal injection
-
Result:Inhibited tumor growth compared to the single agent treatment groups.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized TIGIT Protein, Human can bind Ociperlimab. The EC50 for this effect is 20.39 ng/mL.
Chemical Information
-
CAS No. 2342597-93-5
-
Appearance Liquid
-
Molecular Weight 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Ociperlimab]
-
Synonyms
BGB-A1217
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Chen X, et, al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. Front Immunol. 2022 Feb 22;13:828319. [Content Brief]
[2]. Zhu J, et, al. Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation. Mol Biol Rep. 2022 Dec 26. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ociperlimab Related Classifications
HY-P99763 Related Classifications
Powered by Bioz